WO2021077242A1 - Caspofungin synthesis method and intermediate thereof - Google Patents

Caspofungin synthesis method and intermediate thereof Download PDF

Info

Publication number
WO2021077242A1
WO2021077242A1 PCT/CN2019/112067 CN2019112067W WO2021077242A1 WO 2021077242 A1 WO2021077242 A1 WO 2021077242A1 CN 2019112067 W CN2019112067 W CN 2019112067W WO 2021077242 A1 WO2021077242 A1 WO 2021077242A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
caspofungin
reaction
water
add
Prior art date
Application number
PCT/CN2019/112067
Other languages
French (fr)
Chinese (zh)
Inventor
陈迎会
朱兵峰
Original Assignee
鲁南贝特制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 鲁南贝特制药有限公司 filed Critical 鲁南贝特制药有限公司
Priority to CN201980072867.9A priority Critical patent/CN113286807B/en
Priority to PCT/CN2019/112067 priority patent/WO2021077242A1/en
Publication of WO2021077242A1 publication Critical patent/WO2021077242A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/36Extraction; Separation; Purification by a combination of two or more processes of different types
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid

Definitions

  • the invention belongs to the technical field of medicine, and specifically relates to a method for synthesizing caspofungin and its intermediates.
  • Caspofungin is a echinocandin antifungal agent with a new mechanism of action developed by Merck, and it is also the first echinocandin drug to be marketed (February 2001). Its chemical name is: 1-[(4R,5S)-5-[(2-aminoacetic acid)amino]-N 2 -(10,12-dimethyl-1-carbonyltetradecyl)4-hydroxy- L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine] echinocandin B 0 .
  • the molecular formula is C 52 H 88 N 10 O 15 , and the structural formula is as follows:
  • Caspofungin is an echinocandin antifungal drug approved by the FDA, and has always attracted much attention. There have been many reports on its synthesis and related literature. Its synthesis is based on the biological fermentation product neumocandine B 0 as the starting material. . The synthetic route can be divided into two categories according to the reduction of amide: one is reduction by hydrogen after dehydration of amide to cyano group; the other is direct reduction with borane. There have been many reports on the synthesis of caspofungin in the prior art.
  • CN101648994A reported the use of mercapto aromatic compound R-SH as a stereoselective agent to synthesize caspofungin, where R is phenyl, 4-methoxyphenyl, methylimidazolyl, benzimidazolyl and the like.
  • R is phenyl, 4-methoxyphenyl, methylimidazolyl, benzimidazolyl and the like.
  • CN102367267A describes the use of hydroxyl, benzyloxy, phenoxy, substituted phenoxy, and substituted benzyloxy substituted aromatic ring mercapto compounds R'-SH as a strong leaving group to synthesize caspofungin, preferably p-hydroxy Thiophenol, but it is difficult to avoid the shortcomings of its highly toxic and malodorous.
  • CN102219833A reported the use of stereostructure selector 2-mercaptobenzothiazole or 1-phenyl-5-mercapto-tetrazolium to synthesize caspo
  • CN102112487A reports the use of a nitrogen-containing nucleophile RX-NH to replace a thiol or thiophenol compound as a strong leaving group
  • X is an auxiliary group selected from the group consisting of i) including at least one N-atom as a subgroup Five- and six-membered heterocyclic aromatic rings and derivatives thereof that are part of an amine group, wherein the N-atom constitutes the link to the cyclic hexapeptide; and ii) tetrazole and its derivatives, wherein one nitrogen atom constitutes the ring Connection of hexapeptides.
  • EP620232 and WO94/21677 use the starting material Numocantine B 0 to react with alkyl mercaptan or aryl mercaptan to obtain the sulfone intermediate after oxidation, and then react with amine compound in anhydrous aprotic solvent, and then pass chromatography The method is separated.
  • the selected acid is mainly strong acids such as methanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, trifluoromethanesulfonic acid or trifluoroacetic acid, and the mixing temperature is demanding. Generally in -50 ⁇ -15oC.
  • CN96191834.9 and CN201010144485.3 use borane complex (borane and dimethyl sulfide, diphenyl sulfide and dibenzyl sulfide), boron chloride Caspofungin is obtained by reduction of alkane complex, etc.
  • CN97195496.8 uses borane complex (borane complexed with dimethyl sulfide, diphenyl sulfide, THF, etc.) or metal boride (borane chromium chloride or borane Titanium chloride) is reduced to obtain caspofungin.
  • CN201010538951.6 uses borane and chloroborane for reduction.
  • the present invention provides a method for synthesizing caspofungin and its intermediates. It can effectively solve the problems of three wastes, low yield and low purity.
  • a caspofungin intermediate III its structural formula is as follows:
  • the present invention also provides a method for preparing caspofungin intermediate III. Taking the compound of formula II numocandine B0 as a raw material, it is heated and refluxed with acetone under acid conditions to generate caspofungin intermediate III, the reaction formula is as follows:
  • the mass ratio of the added volume of acetone to numocantine B0 is 10-30:1, mL/g, more preferably 20:1, mL/g.
  • the acid is an inorganic acid or an organic acid, preferably p-toluenesulfonic acid, benzenesulfonic acid, 2,4,5-trimethylbenzenesulfonic acid, acetic acid, concentrated sulfuric acid or concentrated nitric acid, more preferably p-toluenesulfonic acid, benzenesulfonic acid, 2,4,5-trimethylbenzenesulfonic acid, concentrated sulfuric acid or concentrated nitric acid. Toluenesulfonic acid or 2,4,5-trimethylbenzenesulfonic acid.
  • the molar ratio of the acid to numocantine B0 is 0.03 to 0.07:1, preferably 0.05:1.
  • caspofungin intermediate III The following content further details the preparation method of caspofungin intermediate III, including the following steps: adding acetone, molecular sieve, and acid to the reaction system, stirring and dissolving, adding neumocandine B0, heating and refluxing to the end, adding water and acetic acid After the ethyl ester is fully stirred and dissolved, it is allowed to stand for liquid separation. The organic layer is collected, the aqueous phase is extracted with ethyl acetate, the organic phases are combined, washed with water to neutral, dried with magnesium sulfate, filtered, and concentrated. The concentrated solution is crystallized with n-hexane to obtain carbopol Fungin Intermediate III.
  • the molecular sieve is a 3A, 4A or 5A molecular sieve, and the mass ratio of the molecular sieve to Numocantine B0 is 0.1 to 0.3:1.
  • the molecular sieve is a 4A type molecular sieve, and the mass ratio of the molecular sieve to numocantine B0 is 0.2:1.
  • the volume-to-mass ratio of water to neumoconidine B0 is 2-10:1, mL/g, preferably 5:1, mL/g; water and ethyl acetate
  • the volume ratio of ester is 1:2-8, preferably 1:4.
  • the third aspect of the present invention provides a method for preparing caspofungin using caspofungin intermediate III.
  • the reaction solvent in step b is one or more of methanol-water, ethanol-water, isopropanol-water, and acetonitrile-water, more preferably a methanol-water mixed solvent.
  • the volume ratio of methanol, ethanol, isopropanol or acetonitrile to water is 7-12:1, more preferably 9:1.
  • the weak acid resin is a resin containing a carboxylic acid group, a phosphoric acid group or a phenol group. More preferably, the weak acid resin is D110, D113, D151 or D152, and more preferably D113 resin.
  • the mass ratio of the caspofungin intermediate III to the weakly acidic resin is 1:1.5-6, preferably 1:3.
  • the volume mass ratio of ethylenediamine to caspofungin intermediate III in step b is 5.0-7.5:1, mL/g, and more preferably 6.25:1, mL/g.
  • the reducing agent in step c is sodium borohydride and an organic acid
  • the organic acid is selected from one of formic acid, acetic acid, propionic acid, butyric acid, valeric acid, benzoic acid or o-hydroxybenzoic acid, further preferably It is acetic acid.
  • the molar ratio of sodium borohydride to organic acid in step c is 1:1 to 2, preferably 1:1.
  • the molar ratio of caspofungin intermediate IV to sodium borohydride in step c is 1:1 to 2, more preferably 1:1.5.
  • the reaction solvent in step c is one or more of 1,4-dioxane, dimethylsulfoxide, and dimethylimide, preferably 1,4-dioxane.
  • liquid phase preparation and purification process in step c can be carried out according to the prior art or conventional technical methods known in the art, for example, the preparative chromatography in CN106478781A or CN107778360A can be used for purification.
  • the synthetic caspofungin of the present invention has high purity, high yield, low impurity content, simple process steps, safety and environmental protection, strong operability, and is beneficial to large-scale production.
  • the Caspofungin Intermediate III (8.0g, 7.24mmol) was dissolved in a mixed solvent of 50mL methanol and water (methanol-water volume ratio 9:1), then 24.0g D113 resin was added, and then 50mL ethyl acetate was added. Diamine was added dropwise to the reaction system. After the addition, the reaction was stirred at room temperature. HPLC detected that the caspofungin intermediate III was almost exhausted to stop the reaction; filtered, concentrated under reduced pressure, and added 100 mL methanol and 200 mL ethyl acetate The ester was stirred and separated by filtration to obtain solid crystals. The solid crystals were vacuum dried to obtain the compound of formula IV with a purity of 96.85% and a yield of 95.46%.
  • the Caspofungin Intermediate III (8.0g, 7.24mmol) was dissolved in a mixed solvent of 60mL ethanol and water (volume ratio of ethanol to water 7:1), 40.0g D151 resin was added, and then 60mL ethyl acetate was added. The diamine was added dropwise to the reaction system. After the addition was completed, the reaction was stirred at room temperature.
  • the reaction was stopped when the caspofungin intermediate III was almost exhausted by HPLC; filtered, concentrated under reduced pressure, and added 150mL methanol and 200mL ethyl acetate The ester was separated by filtration to obtain solid crystals, and the solid crystals were vacuum-dried to obtain the compound of formula IV with a purity of 93.93% and a yield of 92.74%.
  • caspofungin intermediate III 8.0g, 7.24mmol
  • a mixed solvent of 60mL of acetonitrile and water the volume ratio of acetonitrile to water is 10:1
  • D152 resin the volume ratio of acetonitrile to water is 10:1
  • Diamine was added dropwise to the reaction system. After the addition, the reaction was stirred at room temperature.
  • the caspofungin intermediate III (8.0g, 7.24mmol) was dissolved in a mixed solvent of 60mL methanol and water (methanol-water volume ratio 7:1), 40.0g D151 resin was added, and then 60mL ethyl acetate was added.
  • the diamine was added dropwise to the reaction system. After the addition was completed, the reaction was stirred at room temperature. HPLC detected that Caspofungin Intermediate III was almost exhausted to stop the reaction; filtered, concentrated under reduced pressure, and added 150mL methanol and 250mL acetic acid The ethyl ester was stirred and separated by filtration to obtain solid crystals. The solid crystals were vacuum dried to obtain the compound of formula IV with a purity of 93.46% and a yield of 93.35%.
  • the Caspofungin Intermediate III (8.0g, 7.24mmol) was dissolved in a mixed solvent of 50mL methanol and water (methanol-water volume ratio 3:1), 80.0g D113 resin was added, and 30mL ethyl acetate was added. Diamine was added dropwise to the reaction system. After the addition, the reaction was stirred at room temperature. HPLC detected that the caspofungin intermediate III was almost exhausted to stop the reaction; filtered, concentrated under reduced pressure, and added 100 mL methanol and 200 mL ethyl acetate The ester was stirred and separated by filtration to obtain solid crystals. The solid crystals were vacuum dried to obtain the compound of formula IV with a purity of 92.67% and a yield of 81.68%.
  • the Caspofungin Intermediate III (8.0g, 7.24mmol) was dissolved in a mixed solvent of 50mL methanol and water (methanol-water volume ratio 9:1), 48.0g D751 resin was added, and then 50mL ethyl acetate was added. Diamine was added dropwise to the reaction system. After the addition, the reaction was stirred at room temperature. HPLC detected that the caspofungin intermediate III was almost exhausted to stop the reaction; filtered, concentrated under reduced pressure, and added 100 mL methanol and 200 mL ethyl acetate The ester was stirred and separated by filtration to obtain solid crystals. The solid crystals were vacuum dried to obtain the compound of formula IV with a purity of 88.91% and a yield of 63.45%.
  • the solvent is distilled off under reduced pressure.
  • the concentrate is diluted with methanol and loaded onto the preparative column. Using 0.2% formic acid water as mobile phase A and methanol as mobile phase B for gradient elution, the effluent containing caspofungin was collected and lyophilized to obtain caspofungin with a purity of 99.89% and a yield of 85.96%.
  • the solvent is distilled off under reduced pressure.
  • the concentrated solution is diluted with methanol and loaded onto the preparative chromatography column.
  • % Formic acid water was used as mobile phase A
  • methanol was used as mobile phase B
  • gradient elution was performed, the effluent containing caspofungin was collected, and caspofungin was lyophilized to obtain caspofungin with a purity of 99.81% and a yield of 84.39%.
  • the concentrated solution was diluted with ethanol and loaded on the preparation column with 0.8% formic acid.
  • Water was used as mobile phase A, and acetonitrile was used as mobile phase B for gradient elution.
  • the effluent containing caspofungin was collected and lyophilized to obtain caspofungin with a purity of 99.78% and a yield of 86.03%.
  • the solvent is distilled off under reduced pressure.
  • the concentrate is diluted with methanol and loaded onto the preparative chromatographic column with 0.5% formic acid water as mobile phase A and methanol as the mobile phase.
  • mobile phase B gradient elution was performed, and the effluent containing caspofungin was collected, and caspofungin was lyophilized to obtain caspofungin with a purity of 99.71% and a yield of 85.89%.
  • the concentrated solution was diluted with methanol and loaded onto the preparative column with 0.2% formic acid Water was used as mobile phase A and methanol was used as mobile phase B for gradient elution.
  • the effluent rich in caspofungin was collected and lyophilized to obtain caspofungin with a purity of 99.79% and a yield of 84.57%.
  • the concentrated solution is diluted with methanol and loaded onto the preparative chromatography column with 0.2% formic acid water as the flow In phase A, methanol was used as mobile phase B for gradient elution.
  • the effluent rich in caspofungin was collected and lyophilized to obtain caspofungin with a purity of 97.14% and a yield of 68.51%.
  • Caspofungin is analyzed by 1 H-NMR, 13 C-NMR nuclear magnetic resonance spectroscopy, IR infrared spectroscopy and MS mass spectrometry:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A caspofungin synthesis method and an intermediate compound thereof, the synthesis method using pneumocandin B0 as the starting material and acetone fork protection to obtain a caspofungin intermediate III compound, reacting same with ethylenediamine to obtain caspofungin intermediate IV, and then further reducing same to obtain caspofungin.

Description

一种卡泊芬净的合成方法及其中间体A kind of synthetic method of caspofungin and its intermediate 技术领域Technical field
本发明属于医药技术领域,具体涉及一种卡泊芬净的合成方法及其中间体。The invention belongs to the technical field of medicine, and specifically relates to a method for synthesizing caspofungin and its intermediates.
背景技术Background technique
卡泊芬净(Caspofungin)是由默克公司开发的一种全新作用机制的棘白菌素类抗真菌剂,也是首个上市(2001年2月)的棘白菌素类药物。其化学名称为:1-[(4R,5S)-5-[(2-氨乙酸)氨基]-N 2-(10,12-二甲基-1-羰基十四烷基)4-羟基-L-鸟氨酸]-5-[(3R )-3-羟基-L-鸟氨酸]棘白菌素B 0。分子式为C 52H 88N 10O 15,结构式如下所示: Caspofungin is a echinocandin antifungal agent with a new mechanism of action developed by Merck, and it is also the first echinocandin drug to be marketed (February 2001). Its chemical name is: 1-[(4R,5S)-5-[(2-aminoacetic acid)amino]-N 2 -(10,12-dimethyl-1-carbonyltetradecyl)4-hydroxy- L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine] echinocandin B 0 . The molecular formula is C 52 H 88 N 10 O 15 , and the structural formula is as follows:
Figure 862051dest_path_image001
Figure 862051dest_path_image001
.
卡泊芬净是FDA批准的棘白菌素类抗真菌药物,一直备受关注,关于其合成及相关文献报道已有很多,其合成均是以生物发酵产物纽莫康定B 0为起始原料。合成路线根据酰胺还原的不同可分为两类:一是酰胺脱水变氰基后由氢气还原;二是硼烷直接还原。现有技术对卡泊芬净的合成研究已有很多报道。 Caspofungin is an echinocandin antifungal drug approved by the FDA, and has always attracted much attention. There have been many reports on its synthesis and related literature. Its synthesis is based on the biological fermentation product neumocandine B 0 as the starting material. . The synthetic route can be divided into two categories according to the reduction of amide: one is reduction by hydrogen after dehydration of amide to cyano group; the other is direct reduction with borane. There have been many reports on the synthesis of caspofungin in the prior art.
威廉R.里纳德(William R.Leonard,Jr.,the Journal of Organic Chemistry,2007,7,vol72,2335-2343)使用纽莫康定B 0和苯硫酚合成卡泊芬净,苯硫酚作为立体选择剂,能进行选择性单取代,但苯硫酚的剧毒、恶臭、刺激性气味,不适合工业化生产尤其是批量化药物生产。 William R. Leonard (William R. Leonard, Jr., the Journal of Organic Chemistry, 2007, 7, vol72, 2335-2343) uses neumoconidine B 0 and thiophenol to synthesize caspofungin, thiophenol As a stereoselective agent, it can carry out selective mono-substitution, but the highly toxic, malodorous, and pungent odor of thiophenol is not suitable for industrial production, especially mass production of drugs.
CN101648994A报道了使用巯基芳香化合物R-SH作为立体选择剂合成卡泊芬净,其中R为苯基,4-甲氧基苯基,甲基咪唑基,苯并咪唑基等。CN102367267A则描述了使用羟基、苄氧基、苯氧基、取代苯氧基、取代的苄氧基取代的芳环巯基化合物R'-SH作为强离去基团合成卡泊芬净,优选对羟基苯硫酚,但难以避免其剧毒、恶臭的缺点。CN102219833A报道了使用立体结构选择剂2-巯基苯并噻唑或1-苯基-5-巯基-四氮唑合成卡泊芬净,实际收率不高。CN101648994A reported the use of mercapto aromatic compound R-SH as a stereoselective agent to synthesize caspofungin, where R is phenyl, 4-methoxyphenyl, methylimidazolyl, benzimidazolyl and the like. CN102367267A describes the use of hydroxyl, benzyloxy, phenoxy, substituted phenoxy, and substituted benzyloxy substituted aromatic ring mercapto compounds R'-SH as a strong leaving group to synthesize caspofungin, preferably p-hydroxy Thiophenol, but it is difficult to avoid the shortcomings of its highly toxic and malodorous. CN102219833A reported the use of stereostructure selector 2-mercaptobenzothiazole or 1-phenyl-5-mercapto-tetrazolium to synthesize caspofungin, but the actual yield was not high.
CN102112487A报道了使用含氮亲核试剂RX-NH替代硫醇或硫酚化合物作为强离去基团,X为选自以下组的辅助基团,该组包括i)包括至少一个N-原子作为亚胺基的一部分的五元和六元杂环芳香环及其衍生物,其中所述N-原子构成到环六肽的连接;以及ii)四唑及其衍生物,其中一个氮原子构成到环六肽的连接。虽避免使用恶臭且剧毒的硫醇或硫酚化合物,但又引入了吡啶等剧毒且有刺激性气味的溶剂。CN102112487A reports the use of a nitrogen-containing nucleophile RX-NH to replace a thiol or thiophenol compound as a strong leaving group, and X is an auxiliary group selected from the group consisting of i) including at least one N-atom as a subgroup Five- and six-membered heterocyclic aromatic rings and derivatives thereof that are part of an amine group, wherein the N-atom constitutes the link to the cyclic hexapeptide; and ii) tetrazole and its derivatives, wherein one nitrogen atom constitutes the ring Connection of hexapeptides. Although the use of foul-smelling and highly toxic thiols or thiophenol compounds is avoided, pyridine and other highly toxic and pungent odor solvents are introduced.
EP620232和WO94/21677使用起始原料纽莫康定B 0与烷基硫醇或芳基硫醇反应,经过氧化得到砜中间体,然后与胺化合物在无水的非质子溶剂中反应,再通过色谱方法分离得到。 EP620232 and WO94/21677 use the starting material Numocantine B 0 to react with alkyl mercaptan or aryl mercaptan to obtain the sulfone intermediate after oxidation, and then react with amine compound in anhydrous aprotic solvent, and then pass chromatography The method is separated.
先前报道或公开的使用硫醇或硫酚化合物作为立体选择剂或强离去基团合成卡泊芬净的方法,大多数都是将纽莫康定B 0或卡泊芬净中间体与溶解于酸中的硫醇或硫酚化合物混合,所选的酸主要为甲磺酸、对甲基苯磺酸、樟脑磺酸、三氟甲磺酸或三氟乙酸等强酸,且混合温度要求苛刻,一般在-50~-15ºC。 Previously reported or published methods for synthesizing caspofungin using thiol or thiophenol compounds as stereoselective agents or strong leaving groups, most of which are neumocandine B 0 or caspofungin intermediates dissolved in The thiol or thiophenol compound in the acid is mixed. The selected acid is mainly strong acids such as methanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, trifluoromethanesulfonic acid or trifluoroacetic acid, and the mixing temperature is demanding. Generally in -50~-15ºC.
对纽莫康定B 0中酰胺键的选择性还原,CN96191834.9和CN201010144485.3使用甲硼烷复合物(甲硼烷与二甲硫醚、二苯硫醚和二苄硫醚)、氯硼烷复合物等还原得到卡泊芬净,CN97195496.8使用硼烷络合物(硼烷与二甲硫、二苯硫、THF等络合)或金属硼化物(硼烷氯化铬或硼烷氯化钛)还原得到卡泊芬净,CN201010538951.6使用甲硼烷、氯硼烷进行还原。 For selective reduction of amide bond in Numocantine B 0 , CN96191834.9 and CN201010144485.3 use borane complex (borane and dimethyl sulfide, diphenyl sulfide and dibenzyl sulfide), boron chloride Caspofungin is obtained by reduction of alkane complex, etc. CN97195496.8 uses borane complex (borane complexed with dimethyl sulfide, diphenyl sulfide, THF, etc.) or metal boride (borane chromium chloride or borane Titanium chloride) is reduced to obtain caspofungin. CN201010538951.6 uses borane and chloroborane for reduction.
已公开的合成卡泊芬净的方法在收率、稳定性、纯度和三废等方面不适用于规模化的工业生产。大多数方法需要使用剧毒、恶臭、刺激性气味的硫醇或硫酚化合物,严重损害操作人员的健康,严重污染环境。已有的部分合成方法中,引入氰基,不可避免的导致异构体的生成,收率和立体选择性不高,且使用昂贵金属作为催化剂,提高了工业化成本;多数合成方法使用硼烷及类似物进行还原,硼烷及类似物易挥发、毒性大;多次使用制备色谱,增加工业化成本,且产生大量三废。鉴于此,迫切需要进一步研究适合工业化生产的合成卡泊芬净的方法。The published method for synthesizing caspofungin is not suitable for large-scale industrial production in terms of yield, stability, purity and three wastes. Most methods require the use of highly toxic, foul-smelling, and pungent thiol or thiophenol compounds, which seriously damage the health of operators and seriously pollute the environment. In some of the existing synthesis methods, the introduction of cyano groups inevitably leads to the formation of isomers, the yield and stereoselectivity are not high, and the use of expensive metals as catalysts increases the industrial cost; most synthesis methods use borane and When analogues are reduced, borane and analogues are volatile and toxic; multiple use of preparative chromatography increases industrialization costs and produces a large amount of waste. In view of this, there is an urgent need to further study a method for synthesizing caspofungin suitable for industrial production.
技术问题technical problem
针对现有技术中的不足,本发明提供一种卡泊芬净的合成方法及其中间体。可以有效解决三废、收率低,纯度低等问题。Aiming at the deficiencies in the prior art, the present invention provides a method for synthesizing caspofungin and its intermediates. It can effectively solve the problems of three wastes, low yield and low purity.
技术解决方案Technical solutions
本发明具体技术方案如下:The specific technical scheme of the present invention is as follows:
一种卡泊芬净中间体III,其结构式如下所示:A caspofungin intermediate III, its structural formula is as follows:
Figure 752253dest_path_image002
Figure 752253dest_path_image002
本发明还提供卡泊芬净中间体III的制备方法,以式II化合物纽莫康定B0为原料,在酸条件下与丙酮加热回流反应生成卡泊芬净中间体III,反应式如下:The present invention also provides a method for preparing caspofungin intermediate III. Taking the compound of formula II numocandine B0 as a raw material, it is heated and refluxed with acetone under acid conditions to generate caspofungin intermediate III, the reaction formula is as follows:
Figure dest_path_image003
Figure dest_path_image003
优选地,丙酮的加入体积与纽莫康定B0的质量比为10~30:1,mL/g,更加优选为20:1,mL/g。Preferably, the mass ratio of the added volume of acetone to numocantine B0 is 10-30:1, mL/g, more preferably 20:1, mL/g.
优选地,所述的酸为无机酸或有机酸,优选为,对甲苯磺酸、苯磺酸、2,4,5-三甲基苯磺酸、乙酸、浓硫酸或浓硝酸,进一步优选对甲苯磺酸或2,4,5-三甲基苯磺酸。Preferably, the acid is an inorganic acid or an organic acid, preferably p-toluenesulfonic acid, benzenesulfonic acid, 2,4,5-trimethylbenzenesulfonic acid, acetic acid, concentrated sulfuric acid or concentrated nitric acid, more preferably p-toluenesulfonic acid, benzenesulfonic acid, 2,4,5-trimethylbenzenesulfonic acid, concentrated sulfuric acid or concentrated nitric acid. Toluenesulfonic acid or 2,4,5-trimethylbenzenesulfonic acid.
优选地,所述酸与纽莫康定B0的摩尔比为0.03~0.07:1,优选为0.05:1。Preferably, the molar ratio of the acid to numocantine B0 is 0.03 to 0.07:1, preferably 0.05:1.
以下内容进一步详述卡泊芬净中间体III的制备方法,包括如下步骤,向反应体系中加入丙酮、分子筛、酸,搅拌溶解后加入纽莫康定B0,加热回流反应至结束,加入水和乙酸乙酯充分搅拌溶解后静置分液,收集有机层,水相用乙酸乙酯萃取,合并有机相,水洗至中性后用硫酸镁干燥、过滤、浓缩,浓缩液经正己烷结晶得卡泊芬净中间体Ⅲ。The following content further details the preparation method of caspofungin intermediate III, including the following steps: adding acetone, molecular sieve, and acid to the reaction system, stirring and dissolving, adding neumocandine B0, heating and refluxing to the end, adding water and acetic acid After the ethyl ester is fully stirred and dissolved, it is allowed to stand for liquid separation. The organic layer is collected, the aqueous phase is extracted with ethyl acetate, the organic phases are combined, washed with water to neutral, dried with magnesium sulfate, filtered, and concentrated. The concentrated solution is crystallized with n-hexane to obtain carbopol Fungin Intermediate III.
优选地,所述分子筛的为3A型、4A型或5A型分子筛,分子筛与纽莫康定B0的质量比为0.1~0.3:1。Preferably, the molecular sieve is a 3A, 4A or 5A molecular sieve, and the mass ratio of the molecular sieve to Numocantine B0 is 0.1 to 0.3:1.
进一步优选地,分子筛为4A型分子筛,分子筛与纽莫康定B0的质量比为0.2:1。Further preferably, the molecular sieve is a 4A type molecular sieve, and the mass ratio of the molecular sieve to numocantine B0 is 0.2:1.
优选地,反应结束后加入水和乙酸乙酯后处理,水与纽莫康定B0的体积质量比为2~10:1,mL/g,优选为5:1,mL/g;水和乙酸乙酯的体积比为1:2~8,优选为1:4。Preferably, after the reaction is completed, water and ethyl acetate are added for post-treatment, and the volume-to-mass ratio of water to neumoconidine B0 is 2-10:1, mL/g, preferably 5:1, mL/g; water and ethyl acetate The volume ratio of ester is 1:2-8, preferably 1:4.
本发明的第三方面,提供一种用卡泊芬净中间体Ⅲ制备卡泊芬净的方法。The third aspect of the present invention provides a method for preparing caspofungin using caspofungin intermediate III.
一种卡泊芬净的制备方法,将卡泊芬净中间体Ⅲ在弱酸性树脂的存在下与乙二胺反应生成中间体IV,中间体IV再经硼氢化钠和有机酸还原得到卡泊芬净,反应式如下:A method for preparing caspofungin. Caspofungin intermediate III is reacted with ethylenediamine in the presence of a weak acid resin to form intermediate IV, and intermediate IV is reduced by sodium borohydride and organic acid to obtain caspofungin Fungin, the reaction formula is as follows:
Figure 13470dest_path_image004
Figure 13470dest_path_image004
优选地,步骤b的反应溶剂为甲醇-水、乙醇-水、异丙醇-水、乙腈-水中的一种或几种,进一步优选为甲醇-水的混合溶剂。Preferably, the reaction solvent in step b is one or more of methanol-water, ethanol-water, isopropanol-water, and acetonitrile-water, more preferably a methanol-water mixed solvent.
优选地,甲醇、乙醇、异丙醇或乙腈与水的体积比为7~12:1,更优选为9:1。Preferably, the volume ratio of methanol, ethanol, isopropanol or acetonitrile to water is 7-12:1, more preferably 9:1.
优选地,所述的弱酸性树脂为含有羧酸基、磷酸基或酚基的树脂,进一步优选地,所述弱酸性树脂为D110,D113,D151或D152,更加优选为D113树脂。Preferably, the weak acid resin is a resin containing a carboxylic acid group, a phosphoric acid group or a phenol group. More preferably, the weak acid resin is D110, D113, D151 or D152, and more preferably D113 resin.
优选地,所述卡泊芬净中间体III与弱酸性树脂的质量比为1:1.5~6,优选为1:3。Preferably, the mass ratio of the caspofungin intermediate III to the weakly acidic resin is 1:1.5-6, preferably 1:3.
优选地,步骤b中乙二胺与卡泊芬净中间体Ⅲ的体积质量比为5.0~7.5:1,mL/g,进一步优选为6.25:1,mL/g。Preferably, the volume mass ratio of ethylenediamine to caspofungin intermediate III in step b is 5.0-7.5:1, mL/g, and more preferably 6.25:1, mL/g.
优选地,步骤c中还原剂为硼氢化钠与有机酸,所述的有机酸选自甲酸、乙酸、丙酸、丁酸、戊酸、苯甲酸或邻羟基苯甲酸中的一种,进一步优选为乙酸。Preferably, the reducing agent in step c is sodium borohydride and an organic acid, and the organic acid is selected from one of formic acid, acetic acid, propionic acid, butyric acid, valeric acid, benzoic acid or o-hydroxybenzoic acid, further preferably It is acetic acid.
优选地,步骤c中硼氢化钠与有机酸的摩尔比为1:1~2,优选为1:1。Preferably, the molar ratio of sodium borohydride to organic acid in step c is 1:1 to 2, preferably 1:1.
优选地,步骤c中卡泊芬净中间体IV与硼氢化钠摩尔比为1:1~2,进一步优选为1:1.5。Preferably, the molar ratio of caspofungin intermediate IV to sodium borohydride in step c is 1:1 to 2, more preferably 1:1.5.
优选地,步骤c中反应溶剂为1,4-二氧六环,二甲基亚砜,二甲基亚酰胺中的一种或几种,优选为1,4-二氧六环。Preferably, the reaction solvent in step c is one or more of 1,4-dioxane, dimethylsulfoxide, and dimethylimide, preferably 1,4-dioxane.
下面内容进一步详述卡泊芬净的合成方法,包括如下步骤:The following content further details the synthesis method of caspofungin, including the following steps:
(b)氮气保护下,将卡泊芬净中间体Ⅲ用反应溶剂溶解,加入弱酸性树脂,然后加入乙二胺,室温下反应至结束。过滤,滤液经减压浓缩后,加入甲醇和乙酸乙酯,过滤分离固体,真空干燥得卡泊芬净中间体IV;(B) Under the protection of nitrogen, dissolve caspofungin intermediate III in a reaction solvent, add weak acid resin, and then add ethylenediamine, and react to completion at room temperature. After filtration, the filtrate was concentrated under reduced pressure, methanol and ethyl acetate were added, the solid was separated by filtration, and dried under vacuum to obtain Caspofungin Intermediate IV;
(c)向反应体系中加入硼氢化钠、卡泊芬净中间体IV及反应溶剂,室温氮气保护下搅拌,向另一反应瓶中加入有机酸和反应溶剂,混合搅拌均匀,滴加入上述反应体系中,室温下搅拌反应,反应完毕后,醋酸淬灭反应,减压蒸馏除去有机溶剂,液相制备纯化得卡泊芬净。(C) Add sodium borohydride, caspofungin intermediate IV and reaction solvent to the reaction system, stir under the protection of nitrogen at room temperature, add organic acid and reaction solvent to another reaction flask, mix and stir evenly, add dropwise to the above reaction In the system, the reaction was stirred at room temperature. After the reaction was completed, the reaction was quenched by acetic acid, the organic solvent was removed by distillation under reduced pressure, and the liquid phase was prepared and purified to obtain caspofungin.
需要说明的是步骤c所述液相制备纯化过程可按照现有技术或本领域公知的常规技术方法进行,例如可采用CN106478781A或CN107778360A中的制备色谱进行纯化。It should be noted that the liquid phase preparation and purification process in step c can be carried out according to the prior art or conventional technical methods known in the art, for example, the preparative chromatography in CN106478781A or CN107778360A can be used for purification.
有益效果Beneficial effect
(1)避免使用严重损害操作人员健康及严重污染环境的剧毒、恶臭、刺激性气味的硫醇或硫酚化合物。(1) Avoid using mercaptan or thiophenol compounds that are highly toxic, malodorous, and pungent, which seriously damage the health of operators and seriously pollute the environment.
(2)避免使用具有挥发性、且有毒的硼烷作为还原试剂,而使用硼氢化钠和有机酸反应形成的酰氧硼氢化钠来选择性的还原,得到目的产物,反应条件温和,易于放大。(2) Avoid using volatile and poisonous borane as a reducing agent, and use sodium borohydride and organic acid to form acyloxyborohydride for selective reduction to obtain the target product. The reaction conditions are mild and easy to scale up. .
(3)本发明合成卡泊芬净纯度高,收率高,杂质含量少,工艺步骤简单,安全环保、可操作性强,有利于规模化生产。(3) The synthetic caspofungin of the present invention has high purity, high yield, low impurity content, simple process steps, safety and environmental protection, strong operability, and is beneficial to large-scale production.
本发明的实施方式Embodiments of the present invention
下面通过实施例来进一步阐述本发明,这些实施例仅用于例证的目的,而非任何方式限制本发明的范围。以下实施例中未详尽描述的过程和方法是本领域中公知的常规技术或方法。所用原料、溶剂等如无特别说明均可通过商业途径获得。The following examples are used to further illustrate the present invention. These examples are only for illustrative purposes and do not limit the scope of the present invention in any way. The processes and methods not described in detail in the following embodiments are conventional techniques or methods known in the art. The raw materials and solvents used can be obtained through commercial channels unless otherwise specified.
实施例1Example 1
向反应体系中加入200mL丙酮、2.0g4A分子筛和对甲苯磺酸水合物(89.30mg,0.47mmol),搅拌待对甲苯磺酸溶解后加入纽莫康定B0(10.0g,9.39mmol),氮气保护下,加热回流反应,HPLC跟踪检测反应进程,反应结束后,过滤,浓缩反应液得卡泊芬净中间体Ⅲ粗品。加50mL水和200mL乙酸乙酯,充分搅拌溶解后静置分液,收集有机层,水相用乙酸乙酯萃取(3×100mL),合并有机相,水洗至中性后,用无水硫酸镁干燥,过滤,浓缩;向浓缩液中加入50mL正己烷,回流0.5h后自然降温析晶,得卡泊芬净中间体Ⅲ,HPLC纯度96.67%,收率为92.34%。Add 200mL acetone, 2.0g 4A molecular sieve and p-toluenesulfonic acid hydrate (89.30mg, 0.47mmol) to the reaction system, stir and wait for p-toluenesulfonic acid to dissolve, add numocidine B0 (10.0g, 9.39mmol), under nitrogen protection , The reaction was heated to reflux, and the reaction process was tracked and detected by HPLC. After the reaction was completed, the reaction solution was filtered and the reaction solution was concentrated to obtain the crude caspofungin intermediate III. Add 50mL of water and 200mL of ethyl acetate, stir well to dissolve and then stand for liquid separation, collect the organic layer, extract the aqueous phase with ethyl acetate (3×100mL), combine the organic phases, wash with water to neutral, then use anhydrous magnesium sulfate Dry, filter, and concentrate; add 50 mL of n-hexane to the concentrated solution, reflux for 0.5 h, and then naturally cool down and crystallize to obtain Caspofungin Intermediate III. The HPLC purity is 96.67%, and the yield is 92.34%.
实施例2Example 2
向反应体系中加入300mL丙酮、3.0g 3A分子筛、浓硫酸(0.05mL,0.66mmol),搅拌混匀后加入纽莫康定B0(10.0g,9.39mmol),氮气保护下,加热回流反应,HPLC跟踪检测反应进程,反应结束后,过滤,浓缩反应液得卡泊芬净中间体Ⅲ粗品。加20mL水和100mL乙酸乙酯,充分搅拌溶解后静置分液,收集有机层,水相用乙酸乙酯萃取(3×100mL),合并有机相,水洗至中性后,用无水硫酸镁干燥,过滤,浓缩;向浓缩液中加入80mL正己烷,回流1h后缓慢降温析晶,得卡泊芬净中间体Ⅲ,HPLC纯度93.23%,收率为86.11%。Add 300mL acetone, 3.0g 3A molecular sieves, concentrated sulfuric acid (0.05mL, 0.66mmol) to the reaction system, stir and mix well, add neumoconidine B0 (10.0g, 9.39mmol), under nitrogen protection, heat reflux reaction, HPLC tracking The progress of the reaction was detected, after the reaction was completed, filtered, and the reaction solution was concentrated to obtain the crude caspofungin intermediate III. Add 20 mL of water and 100 mL of ethyl acetate, stir well to dissolve and then stand to separate the layers, collect the organic layer, extract the aqueous phase with ethyl acetate (3×100 mL), combine the organic phases, wash with water until neutral, then use anhydrous magnesium sulfate Dry, filter, and concentrate; add 80 mL of n-hexane to the concentrated solution, reflux for 1 hour and slowly cool down and crystallize to obtain Caspofungin Intermediate III. The HPLC purity is 93.23%, and the yield is 86.11%.
实施例3Example 3
向反应体系中加入100mL丙酮、1.0g 5A分子筛、苯磺酸(44.3mg,0.28mmol),搅拌待苯磺酸溶解后加入纽莫康定B0(10.0g,9.39mmol),氮气保护下,加热回流反应,HPLC跟踪检测反应进程,反应结束后,过滤,浓缩反应液得卡泊芬净中间体Ⅲ粗品。加100mL水和800mL乙酸乙酯,充分搅拌溶解后静置分液,收集有机层,水相用乙酸乙酯萃取(3×100mL),合并有机相,水洗至中性后,用无水硫酸镁干燥,过滤,浓缩;向浓缩液中加入120mL正己烷,回流2h后缓慢降温析晶,得卡泊芬净中间体Ⅲ,HPLC纯度94.28%,收率为88.07%。Add 100mL acetone, 1.0g 5A molecular sieve, benzenesulfonic acid (44.3mg, 0.28mmol) to the reaction system, stir to dissolve the benzenesulfonic acid, then add neumoconidine B0 (10.0g, 9.39mmol), under the protection of nitrogen, heat to reflux During the reaction, the reaction process was tracked and detected by HPLC. After the reaction was completed, the reaction solution was filtered and the reaction solution was concentrated to obtain the crude caspofungin intermediate III. Add 100mL of water and 800mL of ethyl acetate, stir well to dissolve and then stand for liquid separation, collect the organic layer, extract the aqueous phase with ethyl acetate (3×100mL), combine the organic phases, wash with water to neutral, then use anhydrous magnesium sulfate Dry, filter, and concentrate; add 120 mL of n-hexane to the concentrated solution, reflux for 2 hours and slowly cool down and crystallize to obtain Caspofungin Intermediate III. The HPLC purity is 94.28%, and the yield is 88.07%.
实施例4Example 4
向反应体系中加入200mL丙酮、2.0g 4A分子筛、2,4,5-三甲基苯磺酸(112.2mg,0.56mmol),搅拌待2,4,5-三甲基苯磺酸溶解后加入纽莫康定B0(10.0g,9.39mmol),氮气保护下,加热回流反应,HPLC跟踪检测反应进程,反应结束后,过滤,浓缩反应液得卡泊芬净中间体Ⅲ粗品。加60mL水和300mL乙酸乙酯,充分搅拌溶解后静置分液,收集有机层,水相用乙酸乙酯萃取(3×100mL),合并有机相,水洗至中性后,用无水硫酸镁干燥,过滤,浓缩;向浓缩液中加入100mL正己烷,回流0.5h后缓慢降温析晶,得卡泊芬净中间体Ⅲ,HPLC纯度95.92%,收率为91.19%。Add 200mL acetone, 2.0g 4A molecular sieve, 2,4,5-trimethylbenzenesulfonic acid (112.2mg, 0.56mmol) to the reaction system, stir and add after the 2,4,5-trimethylbenzenesulfonic acid is dissolved Numocandine B0 (10.0g, 9.39mmol), under the protection of nitrogen, the reaction was heated and refluxed, and the reaction process was tracked by HPLC. After the reaction, the reaction solution was filtered and the reaction solution was concentrated to obtain the crude caspofungin intermediate III. Add 60mL of water and 300mL of ethyl acetate, stir well to dissolve and then let stand for liquid separation, collect the organic layer, extract the aqueous phase with ethyl acetate (3×100mL), combine the organic phases, wash with water to neutral, then use anhydrous magnesium sulfate Dry, filter, and concentrate; add 100mL n-hexane to the concentrated solution, reflux for 0.5h and slowly cool down and crystallize to obtain Caspofungin Intermediate III. The HPLC purity is 95.92%, and the yield is 91.19%.
实施例5Example 5
向反应体系中加入200mL丙酮、2.0g 4A分子筛、浓硝酸(3.0mg,0.47mmol),搅拌混匀后加入纽莫康定B0(10.0g,9.39mmol),氮气保护下,加热回流反应,HPLC跟踪检测反应进程,反应结束后,过滤,浓缩反应液得卡泊芬净中间体Ⅲ粗品。加50mL水和200mL乙酸乙酯,充分搅拌溶解后静置分液,收集有机层,水相用乙酸乙酯萃取(3×100mL),合并有机相,水洗至中性后,用无水硫酸镁干燥,过滤,浓缩;向浓缩液中加入50mL正己烷,回流0.5h后自然降温析晶,得卡泊芬净中间体Ⅲ,HPLC纯度92.45%,收率为89.66%。Add 200mL acetone, 2.0g 4A molecular sieve, concentrated nitric acid (3.0mg, 0.47mmol) to the reaction system, stir and mix well, add neumocondine B0 (10.0g, 9.39mmol), under nitrogen protection, heat reflux reaction, HPLC tracking The progress of the reaction was detected, and after the reaction was completed, it was filtered and the reaction solution was concentrated to obtain the crude caspofungin intermediate III. Add 50mL of water and 200mL of ethyl acetate, stir well to dissolve and then stand for liquid separation, collect the organic layer, extract the aqueous phase with ethyl acetate (3×100mL), combine the organic phases, wash with water to neutral, then use anhydrous magnesium sulfate Dry, filter, and concentrate; add 50 mL of n-hexane to the concentrated solution, reflux for 0.5 h, and then naturally cool down and crystallize to obtain Caspofungin Intermediate III. The HPLC purity is 92.45%, and the yield is 89.66%.
实施例6Example 6
向反应体系中加入200mL丙酮、2.0g 4A分子筛、乙酸(2.8mg,0.47mmol),搅拌混匀后加入纽莫康定B0(10.0g,9.39mmol),氮气保护下,加热回流反应,HPLC跟踪检测反应进程,反应结束后,过滤,浓缩反应液得卡泊芬净中间体Ⅲ粗品。加50mL水和乙酸乙酯200mL,充分搅拌溶解后静置分液,收集有机层,水相用乙酸乙酯萃取(3×100mL),合并有机相,水洗至中性后,用无水硫酸镁干燥,过滤,浓缩;向浓缩液中加入50mL正己烷,回流0.5h后自然降温析晶,得卡泊芬净中间体Ⅲ,HPLC纯度92.03%,收率为84.85%。Add 200mL acetone, 2.0g 4A molecular sieve, acetic acid (2.8mg, 0.47mmol) to the reaction system, stir and mix well, add neumoconidine B0 (10.0g, 9.39mmol), under nitrogen protection, heat reflux reaction, HPLC tracking detection During the reaction process, after the reaction is completed, filter and concentrate the reaction solution to obtain the crude caspofungin intermediate III. Add 50mL of water and 200mL of ethyl acetate, stir well to dissolve and then stand for liquid separation, collect the organic layer, extract the aqueous phase with ethyl acetate (3×100mL), combine the organic phases, wash with water to neutral, then use anhydrous magnesium sulfate Dry, filter, and concentrate; add 50 mL of n-hexane to the concentrated solution, reflux for 0.5 h, and then naturally cool down and crystallize to obtain Caspofungin Intermediate III. The HPLC purity is 92.03%, and the yield is 84.85%.
实施例7Example 7
向反应体系中加入200mL丙酮、5.0g 4A分子筛、对甲苯磺酸水合物(178.8mg,0.94mmol,0.1eq),搅拌待对甲苯磺酸溶解后加入纽莫康定B0(10.0g,9.39mmol),氮气保护下,加热回流反应,HPLC跟踪检测反应进程,反应结束后,过滤,浓缩反应液得卡泊芬净中间体Ⅲ粗品。加50mL水和200mL乙酸乙酯,充分搅拌溶解后静置分液,收集有机层,水相用乙酸乙酯萃取(3×100mL),合并有机相,水洗至中性后,用无水硫酸镁干燥,过滤,浓缩;向浓缩液中加入50mL正己烷,回流0.5h后自然降温析晶,得卡泊芬净中间体Ⅲ,HPLC纯度88.52%,收率为41.93%。Add 200mL acetone, 5.0g 4A molecular sieve, p-toluenesulfonic acid hydrate (178.8mg, 0.94mmol, 0.1eq) to the reaction system, stir and wait until p-toluenesulfonic acid is dissolved, then add numocantine B0 (10.0g, 9.39mmol) Under the protection of nitrogen, the reaction was heated and refluxed, and the reaction process was tracked and detected by HPLC. After the reaction was completed, the reaction solution was filtered and the reaction solution was concentrated to obtain the crude caspofungin intermediate III. Add 50mL of water and 200mL of ethyl acetate, stir well to dissolve and then stand for liquid separation, collect the organic layer, extract the aqueous phase with ethyl acetate (3×100mL), combine the organic phases, wash with water to neutral, then use anhydrous magnesium sulfate Dry, filter, and concentrate; add 50 mL of n-hexane to the concentrated solution, reflux for 0.5 h and then naturally cool down and crystallize to obtain Caspofungin Intermediate III. The HPLC purity is 88.52%, and the yield is 41.93%.
实施例8Example 8
向反应体系中加入200mL丙酮、2.0g 4A分子筛、2,4,5-三甲基苯磺酸(38.0mg,0.19mmol,0.02eq),搅拌待2,4,5-三甲基苯磺酸溶解后,加入纽莫康定B0(10.0g,9.39mmol),氮气保护下,加热回流反应,HPLC跟踪检测反应进程,反应结束后,过滤,浓缩反应液得卡泊芬净中间体Ⅲ粗品。加60mL水和300mL乙酸乙酯,充分搅拌溶解后静置分液,收集有机层,水相用乙酸乙酯萃取(3×100mL),合并有机相,水洗至中性后,用无水硫酸镁干燥,过滤,浓缩;向浓缩液中加入100mL正己烷,回流0.5h后缓慢降温析晶,得卡泊芬净中间体Ⅲ,HPLC纯度90.66%,收率为73.56%。Add 200mL acetone, 2.0g 4A molecular sieve, 2,4,5-trimethylbenzenesulfonic acid (38.0mg, 0.19mmol, 0.02eq) to the reaction system, and stir for 2,4,5-trimethylbenzenesulfonic acid After dissolving, add Numocantine B0 (10.0g, 9.39mmol), under the protection of nitrogen, the reaction was heated to reflux, and the reaction process was tracked by HPLC. After the reaction, the reaction solution was filtered and the reaction solution was concentrated to obtain the crude caspofungin intermediate III. Add 60mL of water and 300mL of ethyl acetate, stir well to dissolve and then let stand for liquid separation, collect the organic layer, extract the aqueous phase with ethyl acetate (3×100mL), combine the organic phases, wash with water to neutral, then use anhydrous magnesium sulfate Dry, filter, and concentrate; add 100 mL of n-hexane to the concentrated solution, reflux for 0.5 h and slowly cool down and crystallize to obtain Caspofungin Intermediate III. The HPLC purity is 90.66%, and the yield is 73.56%.
实施例9Example 9
向反应体系中加入50mL丙酮、2.0g 4A分子筛、对甲苯磺酸水合物(17.88mg,0.094mmol,0.01eq),搅拌待对甲苯磺酸溶解后加入纽莫康定B0(10.0g,9.39mmol),氮气保护下,加热回流反应,HPLC跟踪检测反应进程,反应结束后,过滤,浓缩反应液得卡泊芬净中间体Ⅲ粗品。加60mL水和300mL乙酸乙酯,充分搅拌溶解后静置分液,收集有机层,水相用乙酸乙酯萃取(3×100mL),合并有机相,水洗至中性后,用无水硫酸镁干燥,过滤,浓缩;向浓缩液中加入100mL正己烷,回流0.5h后缓慢降温析晶,得卡泊芬净中间体Ⅲ,HPLC纯度84.85%,收率为57.34%。Add 50mL acetone, 2.0g 4A molecular sieve, p-toluenesulfonic acid hydrate (17.88mg, 0.094mmol, 0.01eq) to the reaction system, stir and add numocantine B0 (10.0g, 9.39mmol) after p-toluenesulfonic acid is dissolved Under the protection of nitrogen, the reaction was heated and refluxed, and the reaction process was tracked and detected by HPLC. After the reaction was completed, the reaction solution was filtered and the reaction solution was concentrated to obtain the crude caspofungin intermediate III. Add 60mL of water and 300mL of ethyl acetate, stir well to dissolve and then let stand for liquid separation, collect the organic layer, extract the aqueous phase with ethyl acetate (3×100mL), combine the organic phases, wash with water to neutral, then use anhydrous magnesium sulfate Dry, filter, and concentrate; add 100 mL of n-hexane to the concentrated solution, reflux for 0.5 h and slowly cool down and crystallize to obtain Caspofungin Intermediate III with an HPLC purity of 84.85% and a yield of 57.34%.
实施例10Example 10
向反应体系中加入500mL丙酮、5.0g 4A分子筛、2,4,5-三甲基苯磺酸(188.2mg,0.94mmol,0.1eq),搅拌待2,4,5-三甲基苯磺酸溶解后加入纽莫康定B0(10.0g,9.39mmol),氮气保护下,加热回流反应,HPLC跟踪检测反应进程,反应结束后,过滤,浓缩反应液得卡泊芬净中间体Ⅲ粗品。加50mL水和200mL乙酸乙酯,充分搅拌溶解后静置分液,收集有机层,水相用乙酸乙酯萃取(3×100mL),合并有机相,水洗至中性后,用无水硫酸镁干燥,过滤,浓缩;向浓缩液中加入50mL正己烷,回流1h后缓慢降温析晶,得卡泊芬净中间体Ⅲ,HPLC纯度78.73%,收率为43.85%。Add 500mL acetone, 5.0g 4A molecular sieve, 2,4,5-trimethylbenzenesulfonic acid (188.2mg, 0.94mmol, 0.1eq) to the reaction system, and stir until 2,4,5-trimethylbenzenesulfonic acid After dissolving, add Numocantine B0 (10.0g, 9.39mmol), under the protection of nitrogen, the reaction was heated to reflux, and the reaction process was tracked by HPLC. After the reaction, the reaction solution was filtered and the reaction solution was concentrated to obtain the crude caspofungin intermediate III. Add 50mL of water and 200mL of ethyl acetate, stir well to dissolve and then stand for liquid separation, collect the organic layer, extract the aqueous phase with ethyl acetate (3×100mL), combine the organic phases, wash with water to neutral, then use anhydrous magnesium sulfate Dry, filter, and concentrate; add 50 mL of n-hexane to the concentrated solution, reflux for 1 hour and slowly cool down and crystallize to obtain Caspofungin Intermediate III. The HPLC purity is 78.73%, and the yield is 43.85%.
实施例11Example 11
氮气保护下,将卡泊芬净中间体Ⅲ(8.0g,7.24mmol)用50mL甲醇和水的混合溶剂(甲醇-水体积比9:1)溶解后,加入24.0g D113树脂,然后将50mL乙二胺逐滴加至反应体系中,滴加完毕后置于室温下搅拌反应,HPLC检测至卡泊芬净中间体Ⅲ基本耗尽停止反应;过滤,减压浓缩,加入100mL甲醇和200mL乙酸乙酯搅拌、过滤分离得固体结晶,将固体结晶真空干燥得式Ⅳ化合物,纯度96.85%,收率95.46%。Under the protection of nitrogen, the Caspofungin Intermediate III (8.0g, 7.24mmol) was dissolved in a mixed solvent of 50mL methanol and water (methanol-water volume ratio 9:1), then 24.0g D113 resin was added, and then 50mL ethyl acetate was added. Diamine was added dropwise to the reaction system. After the addition, the reaction was stirred at room temperature. HPLC detected that the caspofungin intermediate Ⅲ was almost exhausted to stop the reaction; filtered, concentrated under reduced pressure, and added 100 mL methanol and 200 mL ethyl acetate The ester was stirred and separated by filtration to obtain solid crystals. The solid crystals were vacuum dried to obtain the compound of formula IV with a purity of 96.85% and a yield of 95.46%.
实施例12Example 12
氮气保护下,将卡泊芬净中间体Ⅲ(8.0g,7.24mmol)用50mL异丙醇和水的混合溶剂(异丙醇-水体积比12:1)溶解后,加入48.0g D110树脂,然后将40mL乙二胺逐滴加至反应体系中,滴加完毕后置于室温下搅拌反应,HPLC检测至卡泊芬净中间体Ⅲ基本耗尽停止反应;过滤,减压浓缩,加入100mL甲醇和200mL乙酸乙酯搅拌、过滤分离得固体结晶,将固体结晶真空干燥得式Ⅳ化合物,纯度94.51%,收率91.63%。Under the protection of nitrogen, dissolve Caspofungin Intermediate III (8.0g, 7.24mmol) in 50mL of isopropanol and water mixed solvent (isopropanol-water volume ratio 12:1), add 48.0g D110 resin, and then 40mL of ethylenediamine was added dropwise to the reaction system. After the addition was completed, the reaction was stirred at room temperature. HPLC detected that the caspofungin intermediate III was almost exhausted to stop the reaction; filtered, concentrated under reduced pressure, and added 100mL of methanol and 200 mL of ethyl acetate was stirred and separated by filtration to obtain solid crystals. The solid crystals were vacuum dried to obtain the compound of formula IV with a purity of 94.51% and a yield of 91.63%.
实施例13Example 13
氮气保护下,将卡泊芬净中间体Ⅲ(8.0g,7.24mmol)用60mL乙醇和水的混合溶剂(乙醇和水体积比7:1)溶解后,加入40.0g D151树脂,然后将60mL乙二胺逐滴加至反应体系中,滴加完毕后置于室温下搅拌反应,HPLC检测至卡泊芬净中间体Ⅲ基本耗尽停止反应;过滤,减压浓缩,加入150mL甲醇和200mL乙酸乙酯过滤分离得固体结晶,将固体结晶真空干燥得式Ⅳ化合物,纯度93.93%,收率92.74%。Under the protection of nitrogen, the Caspofungin Intermediate III (8.0g, 7.24mmol) was dissolved in a mixed solvent of 60mL ethanol and water (volume ratio of ethanol to water 7:1), 40.0g D151 resin was added, and then 60mL ethyl acetate was added. The diamine was added dropwise to the reaction system. After the addition was completed, the reaction was stirred at room temperature. The reaction was stopped when the caspofungin intermediate Ⅲ was almost exhausted by HPLC; filtered, concentrated under reduced pressure, and added 150mL methanol and 200mL ethyl acetate The ester was separated by filtration to obtain solid crystals, and the solid crystals were vacuum-dried to obtain the compound of formula IV with a purity of 93.93% and a yield of 92.74%.
实施例14Example 14
氮气保护下,将卡泊芬净中间体Ⅲ(8.0g,7.24mmol)用60mL乙腈和水混合溶剂中(乙腈水体积比为10:1)溶解后,加入30.0g D152树脂,然后将50mL乙二胺逐滴加至反应体系中,滴加完毕后置于室温下搅拌反应,HPLC检测至卡泊芬净中间体Ⅲ基本耗尽停止反应;过滤,减压浓缩,加入100mL甲醇和200mL乙酸乙酯过滤分离得固体结晶,将固体结晶真空干燥得式Ⅳ化合物,纯度95.67%,收率94.56%。Under the protection of nitrogen, dissolve caspofungin intermediate III (8.0g, 7.24mmol) in a mixed solvent of 60mL of acetonitrile and water (the volume ratio of acetonitrile to water is 10:1), add 30.0g of D152 resin, and then add 50mL of acetonitrile to water. Diamine was added dropwise to the reaction system. After the addition, the reaction was stirred at room temperature. HPLC detected that the caspofungin intermediate Ⅲ was almost exhausted to stop the reaction; filtered, concentrated under reduced pressure, and added 100 mL methanol and 200 mL ethyl acetate The ester was separated by filtration to obtain solid crystals, and the solid crystals were vacuum dried to obtain the compound of formula IV with a purity of 95.67% and a yield of 94.56%.
实施例15Example 15
氮气保护下,将卡泊芬净中间体Ⅲ(8.0g,7.24mmol)用60mL甲醇和水的混合溶剂(甲醇-水体积比7:1)溶解后,加入40.0g D151树脂,然后将60mL乙二胺,逐滴加至反应体系中,滴加完毕后置于室温下搅拌反应,HPLC检测至卡泊芬净中间体Ⅲ基本耗尽停止反应;过滤,减压浓缩,加入150mL甲醇和250mL乙酸乙酯搅拌、过滤分离得固体结晶,将固体结晶真空干燥得式Ⅳ化合物,纯度93.46%,收率93.35%。Under the protection of nitrogen, the caspofungin intermediate III (8.0g, 7.24mmol) was dissolved in a mixed solvent of 60mL methanol and water (methanol-water volume ratio 7:1), 40.0g D151 resin was added, and then 60mL ethyl acetate was added. The diamine was added dropwise to the reaction system. After the addition was completed, the reaction was stirred at room temperature. HPLC detected that Caspofungin Intermediate III was almost exhausted to stop the reaction; filtered, concentrated under reduced pressure, and added 150mL methanol and 250mL acetic acid The ethyl ester was stirred and separated by filtration to obtain solid crystals. The solid crystals were vacuum dried to obtain the compound of formula IV with a purity of 93.46% and a yield of 93.35%.
实施例16Example 16
氮气保护下,将卡泊芬净中间体Ⅲ(8.0g,7.24mmol)用50mL甲醇和水的混合溶剂(甲醇-水体积比3:1)溶解后,加入80.0g D113树脂,然后将30mL乙二胺逐滴加至反应体系中,滴加完毕后置于室温下搅拌反应,HPLC检测至卡泊芬净中间体Ⅲ基本耗尽停止反应;过滤,减压浓缩,加入100mL甲醇和200mL乙酸乙酯搅拌、过滤分离得固体结晶,将固体结晶真空干燥得式Ⅳ化合物,纯度92.67%,收率81.68%。Under the protection of nitrogen, the Caspofungin Intermediate III (8.0g, 7.24mmol) was dissolved in a mixed solvent of 50mL methanol and water (methanol-water volume ratio 3:1), 80.0g D113 resin was added, and 30mL ethyl acetate was added. Diamine was added dropwise to the reaction system. After the addition, the reaction was stirred at room temperature. HPLC detected that the caspofungin intermediate Ⅲ was almost exhausted to stop the reaction; filtered, concentrated under reduced pressure, and added 100 mL methanol and 200 mL ethyl acetate The ester was stirred and separated by filtration to obtain solid crystals. The solid crystals were vacuum dried to obtain the compound of formula IV with a purity of 92.67% and a yield of 81.68%.
实施例17Example 17
氮气保护下,将卡泊芬净中间体Ⅲ(8.0g,7.24mmol)用50mL甲醇和水的混合溶剂(甲醇-水体积比9:1)溶解后,加入48.0g D751树脂,然后将50mL乙二胺逐滴加至反应体系中,滴加完毕后置于室温下搅拌反应,HPLC检测至卡泊芬净中间体Ⅲ基本耗尽停止反应;过滤,减压浓缩,加入100mL甲醇和200mL乙酸乙酯搅拌、过滤分离得固体结晶,将固体结晶真空干燥得式Ⅳ化合物,纯度88.91%,收率63.45%。Under the protection of nitrogen, the Caspofungin Intermediate III (8.0g, 7.24mmol) was dissolved in a mixed solvent of 50mL methanol and water (methanol-water volume ratio 9:1), 48.0g D751 resin was added, and then 50mL ethyl acetate was added. Diamine was added dropwise to the reaction system. After the addition, the reaction was stirred at room temperature. HPLC detected that the caspofungin intermediate Ⅲ was almost exhausted to stop the reaction; filtered, concentrated under reduced pressure, and added 100 mL methanol and 200 mL ethyl acetate The ester was stirred and separated by filtration to obtain solid crystals. The solid crystals were vacuum dried to obtain the compound of formula IV with a purity of 88.91% and a yield of 63.45%.
实施例18Example 18
向反应瓶中加入硼氢化钠(256.5mg,6.78mmol)、式Ⅳ化合物(5.0g,4.52mmol)和100mL 1,4-二氧六环,室温氮气保护下搅拌0.5h待用;向另一反应瓶中加入乙酸(0.41g,6.78mmol)和100mL 1,4-二氧六环,搅拌均匀后,氮气置换三次,并将该混合溶液逐滴加至上述反应体系中,滴加完毕后,继续搅拌反应,HPLC检测反应终点,反应完毕后,向反应体系中逐滴加入5.0mL醋酸,滴加完毕后继续反应1h,减压蒸馏除去溶剂,浓缩液用甲醇稀释,上样于制备色谱柱,以0.2%甲酸水作为流动相A,甲醇作为流动相B进行梯度洗脱,收集含卡泊芬净的流出液,冻干得卡泊芬净,纯度99.89%,收率85.96%。Add sodium borohydride (256.5mg, 6.78mmol), compound of formula IV (5.0g, 4.52mmol) and 100mL 1,4-dioxane into the reaction flask, and stir for 0.5h at room temperature under nitrogen protection for use; Add acetic acid (0.41g, 6.78mmol) and 100mL 1,4-dioxane into the reaction flask. After stirring, replace with nitrogen three times, and add the mixed solution dropwise to the above reaction system. After the addition is complete, Continue to stir the reaction. HPLC detects the end of the reaction. After the reaction is completed, 5.0 mL of acetic acid is added dropwise to the reaction system. After the addition is complete, the reaction is continued for 1 hour. The solvent is distilled off under reduced pressure. The concentrate is diluted with methanol and loaded onto the preparative column. Using 0.2% formic acid water as mobile phase A and methanol as mobile phase B for gradient elution, the effluent containing caspofungin was collected and lyophilized to obtain caspofungin with a purity of 99.89% and a yield of 85.96%.
实施例19Example 19
向反应瓶中加入硼氢化钠(171.0mg,4.52mmol)、式Ⅳ化合物(5.0g,4.52mmol)和120mL二甲基亚砜,室温氮气保护下搅拌0.5h待用;向另一反应瓶中加入邻羟基苯甲酸(1.25g,9.04mmol)和150mL二甲基亚砜,搅拌均匀后,氮气置换三次,并将该混合溶液逐滴加至上述反应体系中,滴加完毕后,继续搅拌反应,HPLC检测反应终点,反应完毕后,向反应体系中逐滴加入8.0mL醋酸,滴加完毕后继续反应1h,减压蒸馏除去溶剂,浓缩液用甲醇稀释,上样于制备色谱柱,以0.5%甲酸水作为流动相A,用甲醇作为流动相B,进行梯度洗脱,收集含卡泊芬净的流出液,冻干得卡泊芬净,纯度99.81%,收率84.39%。Add sodium borohydride (171.0mg, 4.52mmol), compound of formula IV (5.0g, 4.52mmol) and 120mL dimethyl sulfoxide into the reaction flask, and stir for 0.5h under the protection of nitrogen at room temperature for use; put into another reaction flask Add o-hydroxybenzoic acid (1.25g, 9.04mmol) and 150mL dimethyl sulfoxide, stir well, replace with nitrogen three times, and add the mixed solution dropwise to the above reaction system. After the addition is complete, continue to stir and react HPLC detects the end of the reaction. After the reaction is completed, 8.0 mL of acetic acid is added dropwise to the reaction system. After the addition is complete, the reaction is continued for 1 hour. The solvent is distilled off under reduced pressure. The concentrated solution is diluted with methanol and loaded onto the preparative chromatography column. % Formic acid water was used as mobile phase A, methanol was used as mobile phase B, gradient elution was performed, the effluent containing caspofungin was collected, and caspofungin was lyophilized to obtain caspofungin with a purity of 99.81% and a yield of 84.39%.
实施例20Example 20
向反应瓶中加入硼氢化钠(342.0mg,9.04mmol)、式Ⅳ化合物(5.0g,4.52mmol)和150mL二甲基亚酰胺,室温氮气保护下搅拌0.5h待用;向另一反应瓶中加入苯甲酸(1.10g,9.04mmol)和150mL二甲基亚酰胺,搅拌均匀后,氮气置换三次,并将该混合溶液逐滴加至上述反应体系中,滴加完毕后,继续搅拌反应,HPLC检测反应终点,反应完毕后,向反应体系中逐滴加入10.0mL醋酸,滴加完毕后继续反应1h,减压蒸馏除去溶剂,浓缩液用乙醇稀释,上样于制备柱上,以0.8%甲酸水为流动相A,乙腈作为流动相B进行梯度洗脱,收集含卡泊芬净的流出液,冻干得卡泊芬净,纯度99.78%,收率86.03%。Add sodium borohydride (342.0mg, 9.04mmol), compound of formula IV (5.0g, 4.52mmol) and 150mL dimethylimide into the reaction flask, and stir for 0.5h under the protection of nitrogen at room temperature for later use; put into another reaction flask Add benzoic acid (1.10g, 9.04mmol) and 150mL dimethylimide. After stirring, replace with nitrogen three times, and add the mixed solution dropwise to the above reaction system. After the addition is complete, continue to stir and react, HPLC The end point of the reaction was detected. After the reaction was completed, 10.0 mL of acetic acid was added dropwise to the reaction system. After the addition, the reaction was continued for 1 hour. The solvent was distilled off under reduced pressure. The concentrated solution was diluted with ethanol and loaded on the preparation column with 0.8% formic acid. Water was used as mobile phase A, and acetonitrile was used as mobile phase B for gradient elution. The effluent containing caspofungin was collected and lyophilized to obtain caspofungin with a purity of 99.78% and a yield of 86.03%.
实施例21Example 21
向反应瓶中加入硼氢化钠(256.5mg,6.78mmol)、式Ⅳ化合物(5.0g,4.52mmol)和100mL 1,4-二氧六环,室温氮气保护下搅拌0.5h待用;向另一反应瓶中加入甲酸(0.42g,9.04mmol)和100mL 1,4-二氧六环,搅拌均匀后,氮气置换三次,并将该混合溶液逐滴加至上述反应体系中,滴加完毕后,继续搅拌反应,HPLC检测反应终点,反应完毕后,向反应体系中逐滴加入5.0mL醋酸,滴加完毕后继续反应1h,减压蒸馏除去溶剂,浓缩液用甲醇稀释,上样于制备色谱柱,以0.5%甲酸水作为流动相A,用甲醇作为流动相B,进行梯度洗脱,收集含卡泊芬净的流出液,冻干得卡泊芬净,纯度99.71%,收率85.89%。Add sodium borohydride (256.5mg, 6.78mmol), compound of formula IV (5.0g, 4.52mmol) and 100mL 1,4-dioxane into the reaction flask, and stir for 0.5h at room temperature under nitrogen protection for use; Add formic acid (0.42g, 9.04mmol) and 100mL to the reaction flask 1,4-Dioxane, after stirring uniformly, nitrogen replacement three times, and the mixed solution was added dropwise to the above reaction system, after the dropwise addition, continue to stir the reaction, HPLC to detect the end of the reaction, after the completion of the reaction, Add 5.0 mL of acetic acid dropwise to the reaction system. After the addition is complete, continue the reaction for 1 hour. The solvent is distilled off under reduced pressure. The concentrate is diluted with methanol and loaded onto the preparative chromatographic column with 0.5% formic acid water as mobile phase A and methanol as the mobile phase. In mobile phase B, gradient elution was performed, and the effluent containing caspofungin was collected, and caspofungin was lyophilized to obtain caspofungin with a purity of 99.71% and a yield of 85.89%.
实施例22Example 22
向反应瓶中加入硼氢化钠(171.0mg,4.52mmol)、式Ⅳ化合物(5.0g,4.52mmol)和100mL二甲基亚砜,室温氮气保护下搅拌0.5h待用;向另一反应瓶中加入丙酸(0.34g,4.52mmol)和100mL二甲基亚砜,搅拌均匀后,氮气置换三次,并将该混合溶液逐滴加至上述反应体系中,滴加完毕后,继续搅拌反应,HPLC检测反应终点,反应完毕后,向反应体系中逐滴加入5.0mL醋酸,滴加完毕后继续反应1h,减压蒸馏除去溶剂,浓缩液用甲醇稀释,上样于制备色谱柱,以0.2%甲酸水作为流动相A,甲醇作为流动相B进行梯度洗脱,收集富含卡泊芬净的流出液,冻干得卡泊芬净,纯度99.79%,收率84.57%。Add sodium borohydride (171.0mg, 4.52mmol), compound of formula IV (5.0g, 4.52mmol) and 100mL dimethyl sulfoxide into the reaction flask, stir for 0.5h under the protection of nitrogen at room temperature for use; put into another reaction flask Add propionic acid (0.34g, 4.52mmol) and 100mL dimethyl sulfoxide, stir well, replace with nitrogen three times, and add the mixed solution dropwise to the above reaction system. After the addition is complete, continue to stir and react, HPLC The end point of the reaction was detected. After the reaction was completed, 5.0 mL of acetic acid was added dropwise to the reaction system. After the addition was completed, the reaction was continued for 1 hour. The solvent was distilled off under reduced pressure. The concentrated solution was diluted with methanol and loaded onto the preparative column with 0.2% formic acid Water was used as mobile phase A and methanol was used as mobile phase B for gradient elution. The effluent rich in caspofungin was collected and lyophilized to obtain caspofungin with a purity of 99.79% and a yield of 84.57%.
实施例23Example 23
向反应瓶中加入硼氢化钠(342.0mg,9.04mmol)、式Ⅳ化合物(5.0g,4.52mmol)和100mL二甲基亚酰胺,室温氮气保护下搅拌0.5h待用;向另一反应瓶中加入戊酸(1.85g,18.08mmol)和100mL二甲基亚酰胺,搅拌均匀后,氮气置换三次,并将该混合溶液逐滴加至上述反应体系中,滴加完毕后,继续搅拌反应,HPLC检测反应终点,反应完毕后,向反应体系中逐滴加入5.0mL醋酸,滴加完毕后继续反应1h,减压蒸馏除去溶剂,浓缩液用甲醇稀释,上样于制备色谱柱,以0.2%甲酸水作为流动相A,甲醇作为流动相B进行梯度洗脱,收集富含卡泊芬净的流出液,冻干得卡泊芬净,纯度99.59%,收率88.17%。Add sodium borohydride (342.0mg, 9.04mmol), compound of formula IV (5.0g, 4.52mmol) and 100mL dimethylimide into the reaction flask, and stir for 0.5h under nitrogen protection at room temperature for later use; put into another reaction flask Add valeric acid (1.85g, 18.08mmol) and 100mL dimethylimide, stir well, replace with nitrogen three times, and add the mixed solution dropwise to the above reaction system. After the addition is complete, continue to stir and react, HPLC The end point of the reaction was detected. After the reaction was completed, 5.0 mL of acetic acid was added dropwise to the reaction system. After the addition was completed, the reaction was continued for 1 hour. The solvent was removed by distillation under reduced pressure. Water was used as mobile phase A and methanol was used as mobile phase B for gradient elution. The effluent rich in caspofungin was collected and lyophilized to obtain caspofungin with a purity of 99.59% and a yield of 88.17%.
实施例24Example 24
向反应瓶中加入硼氢化钠(513.0mg,13.56mmol))、式Ⅳ化合物(5.0g,4.52mmol)和100mL 1,4-二氧六环,室温氮气保护下搅拌0.5h待用;向另一反应瓶中加入丁酸(0.81g,13.56mmol)和100mL 1,4-二氧六环,搅拌均匀后,氮气置换三次,并将该混合溶液逐滴加至上述反应体系中,滴加完毕后,继续搅拌反应,HPLC检测反应终点,反应完毕后,向反应体系中逐滴加入5.0mL醋酸,滴加完毕后继续反应1h,减压蒸馏除去溶剂,浓缩液用甲醇稀释,上样于制备色谱柱,以0.2%甲酸水作为流动相A,甲醇作为流动相B进行梯度洗脱,收集富含卡泊芬净的流出液,冻干得卡泊芬净,纯度97.54%,收率89.09%。Add sodium borohydride (513.0mg, 13.56mmol)), compound of formula IV (5.0g, 4.52mmol) and 100mL 1,4-dioxane to the reaction flask, and stir for 0.5h at room temperature under nitrogen protection for later use; Add butyric acid (0.81g, 13.56mmol) and 100mL 1,4-dioxane to a reaction flask. After stirring, replace with nitrogen three times, and add the mixed solution dropwise to the above reaction system. The addition is complete After that, the reaction was continued to stir, and the end of the reaction was detected by HPLC. After the reaction was completed, 5.0 mL of acetic acid was added dropwise to the reaction system. After the addition, the reaction was continued for 1 hour. The solvent was distilled off under reduced pressure. Chromatographic column, with 0.2% formic acid water as mobile phase A and methanol as mobile phase B for gradient elution, collect the effluent rich in caspofungin, lyophilize to obtain caspofungin, purity 97.54%, yield 89.09% .
实施例25Example 25
向反应瓶中加入硼氢化钠(119.7mg,3.16mmol)、式Ⅳ化合物(5.0g,4.52mmol)和100mL二氯甲烷,室温氮气保护下搅拌0.5h待用;向另一反应瓶中加入三氟乙酸(0.36g,3.16mmol)和100mL二氯甲烷,搅拌均匀后,氮气置换三次,并将该混合溶液逐滴加至上述反应体系中,滴加完毕后,继续搅拌反应,HPLC检测反应终点,反应完毕后,向反应体系中逐滴加入5.0mL醋酸,滴加完毕后继续反应1h,减压蒸馏除去溶剂,浓缩液用甲醇稀释,上样于制备色谱柱,以0.2%甲酸水作为流动相A,甲醇作为流动相B进行梯度洗脱,收集富含卡泊芬净的流出液,冻干得卡泊芬净,纯度97.14%,收率68.51%。Add sodium borohydride (119.7mg, 3.16mmol), compound of formula IV (5.0g, 4.52mmol) and 100mL of dichloromethane to the reaction flask, stir for 0.5h under the protection of nitrogen at room temperature for later use; add three to another reaction flask Fluoroacetic acid (0.36g, 3.16mmol) and 100mL of dichloromethane, after stirring uniformly, nitrogen replacement three times, and the mixed solution was added dropwise to the above reaction system, after the addition is complete, continue to stir the reaction, HPLC detects the end of the reaction After the reaction is complete, add 5.0 mL of acetic acid dropwise to the reaction system, continue the reaction for 1 hour after the addition is complete, and distill under reduced pressure to remove the solvent. The concentrated solution is diluted with methanol and loaded onto the preparative chromatography column with 0.2% formic acid water as the flow In phase A, methanol was used as mobile phase B for gradient elution. The effluent rich in caspofungin was collected and lyophilized to obtain caspofungin with a purity of 97.14% and a yield of 68.51%.
卡泊芬净中间体Ⅲ用 1H-NMR和MS质谱进行分析: Caspofungin intermediate III was analyzed by 1 H-NMR and MS mass spectrometry:
1HNMR(600.13MHz,CD 3OD):7.13(m,1H),7.03(t,2H),6.91(d,1H),6.71(m,2H),6.67(s,1H),4.56(dd,1H),4.42-4.50(m,3H),4.43(dd,1H),4.23(m,3H),4.14(dd,1H),3.89(d,1H),3.69-3.72(m,3H),3.54(d,1H),3.25(d,1H),2.44(m,2H),2.37(dd,1H),2.11-2.15(m,3H),1.86-1.93(m,5H),1.75(s,2H),1.45(m,6H)1.20-1.35(m,15H),0.96(m,2H),0.86(m,1H),0.79(t,3H),0.75-0.78(m,6H); 1 HNMR (600.13MHz, CD 3 OD): 7.13 (m, 1H), 7.03 (t, 2H), 6.91 (d, 1H), 6.71 (m, 2H), 6.67 (s, 1H), 4.56 (dd, 1H), 4.42-4.50 (m, 3H), 4.43 (dd, 1H), 4.23 (m, 3H), 4.14 (dd, 1H), 3.89 (d, 1H), 3.69-3.72 (m, 3H), 3.54 (d, 1H), 3.25 (d, 1H), 2.44 (m, 2H), 2.37 (dd, 1H), 2.11-2.15 (m, 3H), 1.86-1.93 (m, 5H), 1.75 (s, 2H) ),1.45(m,6H)1.20-1.35(m,15H),0.96(m,2H),0.86(m,1H),0.79(t,3H),0.75-0.78(m,6H);
MS(ESI):1105.6027(M+H +)。 MS (ESI): 1105.6027 (M+H + ).
Figure 308448dest_path_image005
的化合物用 1H-NMR和MS质谱进行分析:
formula
Figure 308448dest_path_image005
The compound was analyzed by 1 H-NMR and MS mass spectrometry:
1HNMR(600.13MHZ,CD 3OD):7.13(m,2H),7.03(t,2H),6.71(m,2H),4.89(d,1H),4.85(d,1H),4.60(d,1H),4.56(dd,1H),4.42-4.50(m,2H),4.43(dd,1H),4.23(m,3H),4.14(dd,1H),4.11(d,1H),3.89(d,1H),3.69-3.72(m,3H),3.54(d,1H),3.25(d,1H),2.98(t,2H),2.72-2.95(m,2H),2.44(m,2H),2.37(dd,1H),2.11-2.15(m,3H),1.86-1.93(m,3H),1.75(s,6H),1.20-1.35(m,15H),0.96(m,2H),0.86(m,1H),0.79(t,3H),0.75-0.78(m,6H); 1 HNMR (600.13MHZ, CD 3 OD): 7.13 (m, 2H), 7.03 (t, 2H), 6.71 (m, 2H), 4.89 (d, 1H), 4.85 (d, 1H), 4.60 (d, 1H), 4.56 (dd, 1H), 4.42-4.50 (m, 2H), 4.43 (dd, 1H), 4.23 (m, 3H), 4.14 (dd, 1H), 4.11 (d, 1H), 3.89 (d ,1H), 3.69-3.72 (m, 3H), 3.54 (d, 1H), 3.25 (d, 1H), 2.98 (t, 2H), 2.72-2.95 (m, 2H), 2.44 (m, 2H), 2.37(dd,1H),2.11-2.15(m,3H),1.86-1.93(m,3H),1.75(s,6H),1.20-1.35(m,15H),0.96(m,2H),0.86( m,1H),0.79(t,3H),0.75-0.78(m,6H);
MS(ESI):1108.3215(M+H +)。 MS (ESI): 1108.3215 (M+H + ).
卡泊芬净用 1H-NMR、 13C-NMR核磁共振图谱、IR红外光谱和MS质谱进行分析: Caspofungin is analyzed by 1 H-NMR, 13 C-NMR nuclear magnetic resonance spectroscopy, IR infrared spectroscopy and MS mass spectrometry:
1HNMR(600.13MHz,CD 3OD):7.13(m,2H),6.71(m,2H),4.89(d,1H),4.85(d,1H),4.60(d,1H),4.56(dd,1H),4.42-4.50(m,2H),4.43(dd,1H),4.23(m,3H),4.14(dd,1H),4.11(d,1H),3.89(d,1H),3.69-3.72(m,3H),3.54(d,1H),3.25(d,1H),2.98(t,2H),2.72-2.95(m,4H),2.37(dd,1H),2.11-2.15(m,3H),1.86-1.93(m,5H),1.75(s,6H),1.46(m,2H),1.20-1.35(m,15H),0.96(m,2H),0.86(m,1H),0.79(t,3H),0.75-0.78(m,6H); 1 HNMR (600.13MHz, CD 3 OD): 7.13 (m, 2H), 6.71 (m, 2H), 4.89 (d, 1H), 4.85 (d, 1H), 4.60 (d, 1H), 4.56 (dd, 1H), 4.42-4.50 (m, 2H), 4.43 (dd, 1H), 4.23 (m, 3H), 4.14 (dd, 1H), 4.11 (d, 1H), 3.89 (d, 1H), 3.69-3.72 (m, 3H), 3.54 (d, 1H), 3.25 (d, 1H), 2.98 (t, 2H), 2.72-2.95 (m, 4H), 2.37 (dd, 1H), 2.11-2.15 (m, 3H) ),1.86-1.93(m,5H),1.75(s,6H),1.46(m,2H),1.20-1.35(m,15H),0.96(m,2H),0.86(m,1H),0.79( t,3H),0.75-0.78(m,6H);
13C-NMR(150.9MHZ):176.0,172.8,172.3,172.1,171.4,169.0,167.5,157.2,131.6,128.2,114.9,76.0,74.2,73.7,70.7,67.0,68.7,68.0,66.8,63.0,61.4,57.0,55.8,54.8,54.5,49.8,48.0,47.9,47.8,47.6,47.5,47.3,47.2,45.7,44.5,42.4,38.3,37.6,37.1,36.0,35.2,34.2,33.2,31.5,29.8,29.4,29.3,29.2,29.0,26.7,25.7,19.3,18.8,10.4; 13 C-NMR(150.9MHZ): 176.0, 172.8, 172.3, 172.1, 171.4, 169.0, 167.5, 157.2, 131.6, 128.2, 114.9, 76.0, 74.2, 73.7, 70.7, 67.0, 68.7, 68.0, 66.8, 63.0, 61.4 ,57.0,55.8,54.8,54.5,49.8,48.0,47.9,47.8,47.6,47.5,47.3,47.2,45.7,44.5,42.4,38.3,37.6,37.1,36.0,35.2,34.2,33.2,31.5,29.8,29.4 ,29.3,29.2,29.0,26.7,25.7,19.3,18.8,10.4;
IR(KBr):3775-2348,3345,2920,1634,1545,1461,1231,1093cm -1 IR(KBr): 3775-2348,3345,2920,1634,1545,1461,1231,1093cm -1
MS(ESI):1093.6423(M+H +)。 MS (ESI): 1093.6423 (M+H + ).

Claims (10)

  1. 一种卡泊芬净中间体Ⅲ化合物,其结构式如下所示:
    Figure 950994dest_path_image001
    A caspofungin intermediate III compound, its structural formula is as follows:
    Figure 950994dest_path_image001
    .
  2. 一种卡泊芬净中间体Ⅲ的制备方法,其特征在于,以式II化合物纽莫康定B0为原料,在酸条件下与丙酮加热回流反应生成卡泊芬净中间体III,反应式如下:A method for preparing caspofungin intermediate III, which is characterized in that the compound of formula II numocandine B0 is used as a raw material, and it is heated and refluxed with acetone under acid conditions to generate caspofungin intermediate III. The reaction formula is as follows:
    Figure 375897dest_path_image002
    Figure 375897dest_path_image002
    .
  3. 根据权利要求2所述的制备方法,其特征在于,丙酮的加入体积与纽莫康定B0的质量比为10~30:1,mL/g;更加优选为20:1,mL/g。The preparation method according to claim 2, characterized in that the mass ratio of the added volume of acetone to the mass ratio of Numocantine B0 is 10-30:1, mL/g; more preferably 20:1, mL/g.
  4. 根据权利要求2所述的制备方法,其特征在于,所述的酸为无机酸或有机酸,优选为对甲苯磺酸、苯磺酸、2,4,5-三甲基苯磺酸、乙酸、浓硫酸或浓硝酸,进一步优选对甲苯磺酸或2,4,5-三甲基苯磺酸。The preparation method according to claim 2, wherein the acid is an inorganic acid or an organic acid, preferably p-toluenesulfonic acid, benzenesulfonic acid, 2,4,5-trimethylbenzenesulfonic acid, acetic acid , Concentrated sulfuric acid or concentrated nitric acid, more preferably p-toluenesulfonic acid or 2,4,5-trimethylbenzenesulfonic acid.
  5. 根据权利要求2所述的制备方法,其特征在于,所述酸与纽莫康定B0的摩尔比为0.03~0.07:1,优选为0.05:1。The preparation method according to claim 2, characterized in that the molar ratio of the acid to numocantine B0 is 0.03 to 0.07:1, preferably 0.05:1.
  6. 一种卡泊芬净的合成方法,其特征在于,卡泊芬净中间体Ⅲ在弱酸性树脂的存在下与乙二胺反应生成中间体IV,中间体IV再经硼氢化钠和有机酸还原得到卡泊芬净,反应式如下:A method for synthesizing caspofungin, characterized in that caspofungin intermediate III reacts with ethylenediamine in the presence of a weak acid resin to form intermediate IV, and intermediate IV is reduced by sodium borohydride and organic acid To obtain caspofungin, the reaction formula is as follows:
    Figure 754051dest_path_image003
    Figure 754051dest_path_image003
    .
  7. 根据权利要求6所述的合成方法,其特征在于,步骤b的反应溶剂为甲醇-水、乙醇-水、异丙醇-水、乙腈-水中的一种或几种,进一步优选为甲醇-水的混合溶剂。The synthesis method according to claim 6, wherein the reaction solvent in step b is one or more of methanol-water, ethanol-water, isopropanol-water, and acetonitrile-water, more preferably methanol-water的mixed solvents.
  8. 根据权利要求6所述的合成方法,其特征在于,所述弱酸性树脂为羧酸基、磷酸基或酚基的树脂,优选地,所述弱酸性树脂为D110,D113,D151或D152,进一步优选为D113树脂。The synthesis method according to claim 6, wherein the weakly acidic resin is a carboxylic acid, phosphoric acid or phenol-based resin, preferably, the weakly acidic resin is D110, D113, D151 or D152, and further Preferably it is D113 resin.
  9. 根据权利要求6所述的合成方法,其特征在于,步骤c中,还原剂为硼氢化钠与有机酸,所述的有机酸选自甲酸、乙酸、丙酸、丁酸、戊酸、苯甲酸或邻羟基苯甲酸中的一种,进一步优选为乙酸。The synthesis method according to claim 6, wherein in step c, the reducing agent is sodium borohydride and an organic acid, and the organic acid is selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid, valeric acid, and benzoic acid. Or one of ortho-hydroxybenzoic acid, more preferably acetic acid.
  10. 根据权利要求6所述的合成方法,其特征在于,步骤c中硼氢化钠与有机酸的摩尔比为1:1~2,优选为1:1;步骤c中卡泊芬净中间体IV与硼氢化钠摩尔比为1:1~2,进一步优选为1:1.5。The synthesis method according to claim 6, wherein the molar ratio of sodium borohydride to organic acid in step c is 1:1 to 2, preferably 1:1; in step c, the intermediate IV of caspofungin and The molar ratio of sodium borohydride is 1:1 to 2, more preferably 1:1.5.
PCT/CN2019/112067 2019-10-20 2019-10-20 Caspofungin synthesis method and intermediate thereof WO2021077242A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201980072867.9A CN113286807B (en) 2019-10-20 2019-10-20 Synthesis method and intermediate of caspofungin
PCT/CN2019/112067 WO2021077242A1 (en) 2019-10-20 2019-10-20 Caspofungin synthesis method and intermediate thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/112067 WO2021077242A1 (en) 2019-10-20 2019-10-20 Caspofungin synthesis method and intermediate thereof

Publications (1)

Publication Number Publication Date
WO2021077242A1 true WO2021077242A1 (en) 2021-04-29

Family

ID=75619579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/112067 WO2021077242A1 (en) 2019-10-20 2019-10-20 Caspofungin synthesis method and intermediate thereof

Country Status (2)

Country Link
CN (1) CN113286807B (en)
WO (1) WO2021077242A1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192292A (en) * 1992-09-09 1994-07-12 Fujisawa Pharmaceut Co Ltd Novel polypeptide compound and salt
CN101792486A (en) * 2010-04-12 2010-08-04 浙江海正药业股份有限公司 Method for combining caspofungin acetate
WO2012047762A2 (en) * 2010-10-08 2012-04-12 Amplyx Pharmaceuticals, Inc. Antifungal agents
CN105481952A (en) * 2014-12-24 2016-04-13 上海天伟生物制药有限公司 Nitrogen-heterocycle-hexapeptide-precursor-containing compositions and preparation method and use thereof
CN106478781A (en) * 2015-09-02 2017-03-08 正大天晴药业集团股份有限公司 The preparation method of Caspofungin
CN109721640A (en) * 2017-10-31 2019-05-07 鲁南制药集团股份有限公司 A kind of Caspofungin intermediate and its synthetic method
CN109721641A (en) * 2017-10-31 2019-05-07 鲁南制药集团股份有限公司 A kind of synthetic method of Caspofungin

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06192292A (en) * 1992-09-09 1994-07-12 Fujisawa Pharmaceut Co Ltd Novel polypeptide compound and salt
CN101792486A (en) * 2010-04-12 2010-08-04 浙江海正药业股份有限公司 Method for combining caspofungin acetate
WO2012047762A2 (en) * 2010-10-08 2012-04-12 Amplyx Pharmaceuticals, Inc. Antifungal agents
CN105481952A (en) * 2014-12-24 2016-04-13 上海天伟生物制药有限公司 Nitrogen-heterocycle-hexapeptide-precursor-containing compositions and preparation method and use thereof
CN106478781A (en) * 2015-09-02 2017-03-08 正大天晴药业集团股份有限公司 The preparation method of Caspofungin
CN109721640A (en) * 2017-10-31 2019-05-07 鲁南制药集团股份有限公司 A kind of Caspofungin intermediate and its synthetic method
CN109721641A (en) * 2017-10-31 2019-05-07 鲁南制药集团股份有限公司 A kind of synthetic method of Caspofungin

Also Published As

Publication number Publication date
CN113286807B (en) 2022-09-30
CN113286807A (en) 2021-08-20

Similar Documents

Publication Publication Date Title
RU2682660C9 (en) Method of obtaining pde4 inhibitor
CN105399736B (en) It is a kind of according to the new preparation method of piperazine azoles
JP2009515917A (en) Methods and intermediates for the synthesis of caspofungin
AU2014339136A1 (en) Process for the preparation of a PDE4 inhibitor
WO2019053607A1 (en) Process for preparation of lifitegrast
Chung et al. Cyclic peptide facial amphiphile preprogrammed to self-assemble into bioactive peptide capsules
US20100168415A1 (en) Process for preparation of Caspofungin acetate
WO2020042876A1 (en) Synthesis method for cariprazine
KR20180108669A (en) Process for producing high purity cyclohexenone long-chain alcohol
EP1456229A2 (en) Method for preparing echinocandin derivatives
WO2012062212A1 (en) Preparation method for caspofungin analog
WO2023116664A1 (en) Preparation method for oxidized glutathione and crystal form and impurity thereof
WO2021077242A1 (en) Caspofungin synthesis method and intermediate thereof
CN109721641B (en) Synthesis method of caspofungin
EP2114868A2 (en) Novel polymorphic forms of milnacipran hydrochloride
WO2013131978A1 (en) Process for the preparation of intermediates useful in the preparation of a viral protease inhibitor
WO2011153221A1 (en) Solid state forms of ixabepilone
KR101331984B1 (en) Method of preparing a caspofungin and new intermediates thereof
WO2017191620A1 (en) A crystalline form of a salt of sacubitril and a process of its preparation
CN110818678B (en) Method for preparing cyclohexane derivative
CN106977543A (en) The preparation technology of improved Suo Feibuwei intermediates
CN111039838B (en) Preparation method of 3-acetylmercapto-2-methylpropanoic acid
US20120253007A1 (en) Synthesis of Cyclosporin H
CN111116655B (en) Preparation method of high-optical-purity tenofovir benzyl ester phosphonamide prodrug
WO2005121062A2 (en) Process for the preparation of pravastatin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19949743

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19949743

Country of ref document: EP

Kind code of ref document: A1